Massimo Cristofanilli, MD

Articles

Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer

October 25th 2024

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

Dr. Cristofanilli on Optimal Targeted Therapies in Metastatic HR-Positive Breast Cancer

October 5th 2022

Massimo Cristofanilli, MD, discusses the variety of targeted therapies available in metastatic hormone receptor–positive breast cancer.

Dr. Cristofanilli on the Need for Biosimilars in Oncology

December 16th 2019

Massimo Cristofanilli, MD, discusses the need for biosimilars in oncology.

Dr. Cristofanilli on Aromatase Inhibitor Adverse Events in Breast Cancer

October 30th 2019

Massimo Cristofanilli, MD, discusses adverse events caused by the use of aromatase inhibitors in breast cancer.

Dr. Cristofanilli on Data With Lasofoxifene in ESR1-Mutant Breast Cancer

October 9th 2019

Massimo Cristofanilli, MD, professor of medicine, Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses data with lasofoxifene in women with ESR1-mutant breast cancer.

Dr. Cristofanilli on Lasofoxifene in ESR1-Mutant Breast Cancer

October 4th 2019

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the use of lasofoxifene in ESR1-mutant breast cancer.

Dr. Cristofanilli on Using CTC to Stratify Patients With Breast Cancer

January 31st 2019

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses using circulating tumor cells to risk stratify patients with advanced breast cancer.

Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial

October 20th 2018

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Dr. Cristofanilli Discusses Roles of a Multidisciplinary Team in Breast Cancer

October 14th 2018

Massimo Cristofanilli, MD, discusses a session at the 20th Annual Lynn Sage Breast Cancer Symposium on the roles of a multidisciplinary team.

Dr. Cristofanilli on Endocrine Therapy for Breast Cancer

September 17th 2017

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endocrine therapy for patients with breast cancer.

Dr. Cristofanilli on the PALOMA3 Trial for Breast Cancer

June 3rd 2015

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

CTC Testing Offers Current Value and Future Promise in MBC

January 6th 2015

Circulating tumor cell (CTC) enumeration is a strong prognostic factor in metastatic breast cancer (MBC) and predicts treatment failure.

Dr. Cristofanilli Discusses ALK Amplification in IBC

October 23rd 2012

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.